종양학 NGS 시장 : 기술, 제품 및 서비스, 용도별 - 세계 예측(2025-2030년)

The Oncology NGS Market was valued at USD 438.26 million in 2023, expected to reach USD 504.37 million in 2024, and is projected to grow at a CAGR of 15.48%, to USD 1,200.39 million by 2030.

Oncology Next-Generation Sequencing (NGS) refers to advanced genomic sequencing technologies used to analyze cancer genomes more swiftly and economically than traditional methods, providing detailed insights necessary for personalized cancer treatment. The NGS market in oncology is driven by the increasing demand for precision medicine, as it allows for the identification of specific genetic mutations and helps tailor targeted therapies, essential for effective cancer management. This application extends across various end uses like hospitals, research institutions, and pharmaceutical companies who utilize NGS for diagnostics, therapy decisions, and monitoring patient progress. Factors influencing market growth include the technological advancements in NGS platforms that have significantly reduced sequencing costs, rising incidences of cancer globally necessitating precise treatment strategies, and increasing government and private funding in genomic research. However, the market faces limitations from challenges such as the high complexity involved in data interpretation, stringent regulatory frameworks, and the high initial investment cost for setting up NGS laboratories. Despite these challenges, evolving opportunities exist through partnerships with bioinformatics companies to manage and interpret NGS data, and through collaborations that lead to innovative NGS-based diagnostic and therapeutic solutions. Furthermore, addressing gaps in the existing infrastructure, especially in emerging markets, presents growth potential. For business growth, areas ripe for innovation include the development of user-friendly bioinformatics tools, enhancement in multiplexing capabilities to cover more genes in a single assay, and the exploration of liquid biopsy technologies as a non-invasive diagnostic solution. Given the dynamic nature of the market, staying informed of the latest technological advancements, regulatory changes, and competitive landscape shifts is crucial for identifying and seizing opportunities. Overall, the market for oncology NGS holds significant promise for businesses that prioritize agile adaptation and continuous innovation.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Oncology NGS Market

The Oncology NGS Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Potential demand attributed to rising prevalence of cancer incidence globally
  • Growing popularity of personalized medicine in clinical oncology
  • Increasing consumer adoption owing to decreasing costs for genetic sequencing solutions
• Market Restraints
  • Lack of computational efficiency for data management
• Market Opportunities
  • Rising governmental initiatives and investments in the field of research and development in oncology
  • Emerging advancements for whole-genome sequencing worldwide
• Market Challenges
  • Limited and inadequate reimbursement policies

Porter's Five Forces: A Strategic Tool for Navigating the Oncology NGS Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Oncology NGS Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Oncology NGS Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Oncology NGS Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Oncology NGS Market

A detailed market share analysis in the Oncology NGS Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Oncology NGS Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Oncology NGS Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Oncology NGS Market

A strategic analysis of the Oncology NGS Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Oncology NGS Market, highlighting leading vendors and their innovative profiles. These include 4basecare Onco Solutions Private Limited, BGI Group, Caris Life Sciences, Eurofins Scientific SE, Foundation Medicine, Inc., Genotypic Technology Pvt. Ltd., Hologic, Inc., MedGenome, Myriad Genetics, Inc., PerkinElmer Inc., Premas Life Sciences, Sayre Therapeutics Pvt Ltd., SciGenom Labs Pvt. Ltd., Tecan Trading AG, Vela Diagnostics Holding Pte Ltd., and Xcelris Labs Ltd..

Market Segmentation & Coverage

This research report categorizes the Oncology NGS Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Technology, market is studied across Amplicon-based, Hybridization-based, Targeted & Gene Panel Sequencing, Whole Exome Sequencing, and Whole Genome Sequencing.
• Based on Product & Service, market is studied across Platforms & Related Products and Services. The Platforms & Related Products is further studied across Consumables, Panels, and Platforms. The Services is further studied across By Workflow, NGS Data Analysis, NGS Pre-Sequencing, NGS Primary Data Analysis, NGS Secondary Data Analysis, NGS Sequencing, and NGS Tertiary Data Analysis.
• Based on Application, market is studied across Academic & Clinical Research, Hospitals & Clinics, and Pharma & Biotech Entities.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Potential demand attributed to rising prevalence of cancer incidence globally
    • 5.1.1.2. Growing popularity of personalized medicine in clinical oncology
    • 5.1.1.3. Increasing consumer adoption owing to decreasing costs for genetic sequencing solutions
  • 5.1.2. Restraints
    • 5.1.2.1. Lack of computational efficiency for data management
  • 5.1.3. Opportunities
    • 5.1.3.1. Rising governmental initiatives and investments in the field of research and development in oncology
    • 5.1.3.2. Emerging advancements for whole-genome sequencing worldwide
  • 5.1.4. Challenges
    • 5.1.4.1. Limited and inadequate reimbursement policies
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Oncology NGS Market, by Technology

• 6.1. Introduction
• 6.2. Amplicon-based
• 6.3. Hybridization-based
• 6.4. Targeted & Gene Panel Sequencing
• 6.5. Whole Exome Sequencing
• 6.6. Whole Genome Sequencing

7. Oncology NGS Market, by Product & Service

• 7.1. Introduction
• 7.2. Platforms & Related Products
  • 7.2.1. Consumables
  • 7.2.2. Panels
  • 7.2.3. Platforms
• 7.3. Services
  • 7.3.1. By Workflow
  • 7.3.2. NGS Data Analysis
  • 7.3.3. NGS Pre-Sequencing
  • 7.3.4. NGS Primary Data Analysis
  • 7.3.5. NGS Secondary Data Analysis
  • 7.3.6. NGS Sequencing
  • 7.3.7. NGS Tertiary Data Analysis

8. Oncology NGS Market, by Application

• 8.1. Introduction
• 8.2. Academic & Clinical Research
• 8.3. Hospitals & Clinics
• 8.4. Pharma & Biotech Entities

9. Americas Oncology NGS Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Oncology NGS Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Oncology NGS Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. 4basecare Onco Solutions Private Limited
• 2. BGI Group
• 3. Caris Life Sciences
• 4. Eurofins Scientific SE
• 5. Foundation Medicine, Inc.
• 6. Genotypic Technology Pvt. Ltd.
• 7. Hologic, Inc.
• 8. MedGenome
• 9. Myriad Genetics, Inc.
• 10. PerkinElmer Inc.
• 11. Premas Life Sciences
• 12. Sayre Therapeutics Pvt Ltd.
• 13. SciGenom Labs Pvt. Ltd.
• 14. Tecan Trading AG
• 15. Vela Diagnostics Holding Pte Ltd.
• 16. Xcelris Labs Ltd.